University City, MO, United States of America

Benjamin Pomerantz



Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2007

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: **Inventor Profile: Benjamin Pomerantz**

Introduction

Benjamin Pomerantz, an innovative inventor based in University City, Missouri, has made significant contributions to the field of biomedical research. His work focuses on crucial methodologies that address significant challenges in the medical sector.

Latest Patents

Pomerantz holds a patent for "Nucleic acids, polypeptides, and methods for modulating apoptosis." This invention provides methods for identifying ischemia incidences in mammalian tissue, particularly in heart tissue. His research employs the measurement and comparison of gene expression levels, specifically apoptosis-specific eIF-5A compared to proliferating eIF-5A. When apoptosis-specific eIF-5A levels exceed those of proliferating eIF-5A, it signals an incident of ischemia. Furthermore, his novel approach offers a method to reduce apoptosis in mammalian tissue through agents that inhibit the expression of apoptosis-specific eIF-5A, with preferred agents being antisense oligonucleotides targeted at this specific factor.

Career Highlights

Pomerantz's career has been defined by his role at Senesco Technologies, Inc., where he has been able to implement his research into practical applications. His contributions are instrumental in the development of therapies aimed at mitigating cell death in cardiac tissue, providing potential avenues for the treatment of heart-related ailments.

Collaborations

Throughout his career, Pomerantz has collaborated with notable peers such as John E. Thompson and Catherine Taylor. These collaborations have enriched his research, enabling the fusion of ideas and innovation in the pursuit of medical advancements.

Conclusion

Benjamin Pomerantz exemplifies the spirit of innovation within the field of biomedical research. Through his patented methodologies, he has developed vital processes that may redefine how ischemia is diagnosed and treated. His ongoing work at Senesco Technologies, Inc. continues to push the boundaries of what is possible in the realm of healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…